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Treatment naïve psychiatric patientsa b s t r a c t
Background: Psychiatric disorders contribute significantly to the global burden of diseases. There is an
urgent need to curtail the morbidity and mortality associated with psychiatric disorders. Deficiencies
of cobalamin and folate have been linked with psychiatric disorders.
Materials and method: Sixty-six each of antipsychotic treatment, treatment naïve psychiatric patients and
control were recruited for the study. Red cell folate and serum cobalamin were determined with Enzyme
Linked Immunosorbent Assay kits and the haemogram using Sysmex XT2000i.
Result: Folate deficiency was present in 13.6% of newly diagnosed anti-psychotic naive psychiatric
patients with few of them having neutrophil hypersegmentation (7.6%) and macrocytosis (4.5%). Mean
red cell folate levels for anti-psychotic naïve, patients on anti-psychotic and controls were
350.23 ± 0.54 nmol/l, 370 ± 0.70 nmol/l and 370 ± 0.51 nmol/l respectively, with p-values of 0.0001 and
0.3500 respectively when compared with control, while serum cobalamin levels were within the normal
reference range in all patients and controls.
Reticulocyte count had 8 times and 3 times likelihood of influencing low serum folate and low serum
cobalamin respectively.
Conclusion: All patients had Serum cobalamin levels within the reference interval, the same can be said of
the RBC folate levels of the greater percentage (95.5%) of psychiatric patients on psychotropic drugs.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psychiatric disorders contribute significantly to the global bur-
den of diseases.1 Worst still, projections by experts have shown an
expected increase in the burden by 2020.2 There is therefore an
urgent need to curtail the morbidity and mortality associated with
psychiatric disorders.
Deficiencies of cobalamin and folate have been linked with
dementia, psychosis and other psychiatric disorders.3–6 Deficien-
cies of both vitamins and development of psychiatric disorders
play causal role to each other.6 A review study conducted by MA
Arroll and co-workers has highlighted a number of possible con-
tributory mechanisms which included oxidative stress, one carbon
metabolism (Folate and vitamin B12 metabolism), essential fattyacids insufficiency and immune-mediated responses in the patho-
physiology of schizophrenia.7 Progression to psychiatric disorders
due to deficiencies of the vitamins has been attributed to failure
of synthesis of S-adenosylmethionine (SAM) due to blockage in
the conversion of homocysteine to methionine,3 while develop-
ment of deficiencies in the course of psychiatric disorders is due
to the use of antipsychotic agents.
For the detection of cobalamin and folate deficiencies, highly
sensitive serum methylmalonic acid (MMA) and homocysteine
levels would have been more appropriate in the diagnosis of
patients with psychiatric disorders. Assay for MMA is complex
and the cost of reagents highly exorbitant and not readily available
while homocysteinaemia is also found in patients with Chronic
Renal Failure,8 in alcoholism9 and smoking10 making its detection
not specific for cobalamin and folate deficiencies.
With reduced sensitivity of serum cobalamin notwithstanding,
there is still no universally acceptable alternative.11 Serum folate
is also markedly affected by recent diet.3,11 Red blood cells can
store high levels of folate3 and it is an indicator of tissue folate
status since it indicates overall folate turnover in the preceding
2–3 months.12
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sufficient in detecting appreciable number of patients with
low levels of vitamins B12 and folate if deficiencies are truly
present.
Early detection and correction of deficiencies of these vita-
mins have been shown to reverse or reduce progression of psy-
chiatric disorders and prevents long term use of anti-
psychotics.13 Studies have also shown that the best response to
antipsychotic treatment occurs if cobalamin deficiency is
reversed within the first 6 months of commencing treatment.13
Damage becomes irreversible if deficiency is not reversed within
12 months, hence the need for early detection and correction of
the deficiencies.13
Several studies conducted locally and internationally have only
shown conflicting results. Most of the studies reported low levels
of both vitamins,14,15 while others reported low level of red cell
folate with high level of serum cobalamin.16
The aim of this study was therefore to assess serum cobalamin
level and red cell folate of psychiatric patients on antipsychotics
and those that are antipsychotic-naïve and compare the results
with that of the previous studies. The study aimed at determining
the influence of antipsychotics on the genesis and severity of
cobalamin and folate deficiencies.2. Materials and method
Study Area: This study was carried out at the Psychiatric Out-
Patient Clinic and Department of Haematology and Blood Transfu-
sion of University of Ilorin Teaching Hospital (UITH), Ilorin, Nigeria.
UITH is a five star, 504 bedded hospital located at the North Central
region of Nigeria. The hospital serves as referral centre for most
other hospitals in the region with an estimated population of about
15,450,08417
General Adult Psychiatric Clinics are run on Mondays, Tuesdays
and Thursdays where patients were reviewed by consultant beha-
vioural scientists.
Study design: it was a cross sectional descriptive case control
study.
Study population: consisted of
1. Newly diagnosed, anti-psychiatric naïve patients.
2. Psychiatric patients already on antipsychotics medication on
follow-up.
3. Routine blood donors who were certified fit to donate blood and
assessed to be free of psychiatric ailments using General health
Questionnaire-12 (GHQ-12) served as case controls.
GHQ-12 is a 12 item versions and self administered question-
naire used to screen for psychiatric morbidity. Its use has been val-
idated in this environment, with a cut-off of 3.18
Sample technique: a multi-staged technique where all newly
presenting antipsychotic-naïve patients who certified inclusion
criteria were recruited until the required number was obtained.
For those on antipsychotics for follow-up, only those registered
with even numbers were recruited for the study. The reason for
this was because our data showed that patients on follow-up
out-numbered newly presenting ones several folds. Equal number
of controls was also recruited for the study.
Inclusion criteria for study population:
1. Adult newly diagnosed antipsychotic naïve psychiatric patients
aged 18–65 years who met ICD-10 criteria.19
2. Adult psychiatric patients on anti-psychotics who met ICD-10
criteria.19Exclusion criteria for study population:
3. Presence of chronic co-morbidity/ies like hypertension, Dia-
betes mellitus.
4. Psychiatric patients on haematinics or multivitamins.
Inclusion criteria for controls:
5. Blood donors not on haematinics or multivitamins.
6. Blood donors with no physical morbidity.
Exclusion criteria for controls:
7. Blood donors with GHQ-12 >3.
8. Blood donors who did not give consent.
Sample size: Sixty-six (66) each of the study populations and
controls were used based on the formula by AraoyeMO.20
Ethical issues: Ethical clearance was obtained from UITH
Ethical Research Committee. Written permission was also
obtained from Heads of Psychiatry and Haematology depart-
ments and Consultants in charge of the patients. A signed
informed consent was obtained from every participant before
being recruited.
Every participant was given a number to ensure confidential-
ity. All pieces of information were kept confidential. There was
no harm to participants except for slight discomfort during
venepuncture. No financial burden on the participants and no
punitive measure against those who declined to participate in
the study.
Methodology: Eight milliliters of venous blood was obtained
aseptically from all patients. Four milliliters each was dispensed
into EDTA and plain vacuitainer bottles.
Samples in EDTA bottle: into this sample, 2 ml of 0.2% ascorbic
acid16 was added, thoroughly mixed and stored at 20 C until
analyzed for red cell folate.
Samples in plain bottle: from this sample, sera was obtained by
centrifugation and also stored at 70 C until analyzed for serum
cobalamin.
Assay:
1. Red cell folate: Diagnostic Automation Folic acid quantitative
Enzyme Linked Immuno Sorbent Assay (ELISA) test using Folate
ELISA Test Kit was used to estimate red cell folate on every
sample.
2. Serum cobalamin: Diagnostic Automation vitamin B12 quantita-
tive ELISA test using Vitamin B12 ELISA Test Kit was also used to
estimate for serum cobalamin.
3. Haemogram: Full Blood Count (MCH, MCHC, MCV, PCV, Platelet
count, Reticulocytes count, Reticulocytes index and Total white
blood cell count) was determined on every sample using Sys-
mex XT2000i automated cell counter.
In each case, manufacturer’s instruction manual was strictly
adhered to.
Data Analysis: data entry and analysis was done using EPI Info
version 3.5.1. Results were presented in tabular forms. Mean val-
ues of the three groups of respondents were compared and multi-
ple logistic progressions carried out to determine the factors
influencing serum cobalamin and red cell folate. A linear relation-
ship between serum cobalamin and red cell folate was also
determined.
Statistical significance was tested at a predetermined p-value of
<0.05.
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Socio-demographic pattern: About half (51.5%) and slightly lower
(47%) of anti-psychotropic-naïve patients and patients on anti-
psychotic respectively were young adults, while slightly more
(53%) of patients on antipsychotics were middle aged. Two (3%),
each of anti-psychotic naïve patients and controls were above
60 years of age, Table 1.
Male patients (57.6%), predominated the anti-psychotic naïve
group while female patients (51.5%) predominated the group on
anti-psychotics, Table 2.
Schizophrenia was the diagnosis in the majority of patients,
86.4% and 91% respectively in anti-psychotic naïve and anti-
psychotic treatment groups. Other diagnoses were depressive
illness (6.1% of anti-psychotic naïve and 4.5% of patients on anti-
psychotics), substance use disorder (3% of anti-psychotic naïve
and 4.5% of patients on anti-psychotics) and dementia in 1.5% of
anti-psychotic naïve patients.Table 1







Frequency n (%) Frequency n (%) Frequency n (%)
Age group
18–40 34 (51.5) 31 (47.0) 33 (50.0)
41–60 30 (45.5) 35 (53.0) 31 (47.0)
>60 2 (3.0) 0 (0.0) 2 (3.0)
Sex
Male 38 (57.6) 32 (48.5) 35 (53.0)
Female 28 (42.4) 34 (51.5) 31 (47.0)
Table 2
Psychiatric diagnoses of participants (Drug-naïve and those on treatment).
Diagnoses Drug-naïve subjects (%) Subjects on
anti-psychotics (%)
1. Schizophrenia 86.50 91.00
2. Depressive illness 6.10 4.50
3. Substance use disorder 3.00 4.50
4. Mania 3.00 –
5. Dementia 1.50 –
Table 3
Comparing serum cobalamin and red cell folate of anti-psychotic naïve subjects with that
Variables Subjects Control
Mean ± SD Mean ± SD
Cobalamin (pmol/L) 160.79 ± 1.17 160.77 ± 0.89
140.2–180.5 141.3–179.1
Folate (nmol/L) 350.23 ± 0.54 370.07 ± 0.51
350.5–380 357.1–378.5
Table 4
Comparing serum cobalamin and red cell folate of subjects on anti-psychotic with that of
Variables Subjects Control
Mean ± SD Mean ± SD
Cobalamin (pmol/L) 160.84 ± 0.73 160.77 ± 0.89
140.2–180.5 141.3–179.1
Folate (nmol/L) 370.17 ± 0.70 370.07 ± 0.51
350.5–380 357.1–378.5Red cell folate: Nine (13.6%) of the anti-psychotic naïve patients
and 3 (4.5%) of patients on anti-psychotics had red cell folate below
360 nmol/l while all our controls had red cell folate within normal
reference range of 360-1460 nmol/.11,21 Mean red cell folate levels
for anti-psychotic naïve, patients on anti-psychotic and controls
were 350.23 ± 0.54 nmol/l, 370 ± 0.70 nmol/l and 370 ± 0.51 nmol/
l respectively. Compared with control, the p-values for anti-
psychotic naïve patients and patients on anti-psychotic were
0.0001 and 0.3500 respectively, Tables 3 and 4.
Serum cobalamin: serum cobalamin levels were evenly dis-
tributed and within the normal reference range of 20–680 pmol/11
in all patients and controls with p-values 0.9122 and 0.6221 for
anti-psychotic naïve and patients on ant-psychotic when com-
pared with controls, Tables 3 and 4.
Comparison of the variables amongst the three groups of subjects:
When these variables were compared amongst the three groups of
subjects, serum cobalamin and red cell folate had p-values of 0.641
and 0.002 respectively, Table 5.
Logistic regression model of predictors of serum cobalamin and red
cell folates levels: This was built using the parameters of haemo-
gram as predictors of serum cobalamin and red cell folate status.
Reticulocyte count had about 8 times the likelihood of influencing
low red cell folate, though not statistically significant (odds ratio =
8.18; 95% CI = 0.010 > 1.000; p = 0.156) and about 3 times the like-
lihood of influencing low serum cobalamin, also not statistically
significant (odds ratio = 2.90, 95% CI = 0.025 > 1.000, p = 0.094),
Table 6. None of the other factors in haemogram had statististically
significant influence on neither low red cell folate nor low serum
cobalamin levels, Table 6.
4. Discussion
A total of 198 subjects were recruited into this study. This com-
prises of 66 each of anti-psychotic treatment, treatment naïve psy-
chiatric patients and healthy blood donors as controls.
Schizophrenia was the commonest diagnosis among all patients;
hence significant findings were made in this group of subjects.
From this study, the prevalence of red cell folate deficiency
was 13.6% and 4.5% in anti-psychotic naïve psychiatric patients
and psychiatric patients on anti-psychotics. This value is high
compared with 3% seen among the general population. Five
out of nine anti-psychotic naïve psychiatric patients with low
red cell folates were also found to have neutrophil hyperseg-












Comparison of mean values of parameters in the 3 groups (Analysis of Variance – ANOVA).
Parameters Study groups n Mean ± SD df F-test P-value
Cobalamin (pmol/l) Control 66 16.77 ± 0.89
Naive 66 16.79 ± 1.17 2 0.45 0.641
Treatment 66 16.84 ± 0.73
Folate (nmol/l) Control 66 37.07 ± 0.51
Naïve 66 35.23 ± 0.54 2 6.71 0.002
Treatment 66 37.17 ± 0.70
Table 6
Logistic regression of factors predicting Serum Cobalamin and red cell folate levels.
Haemogram Variables P-value Odds ratio 95% confidence interval
MCH Serum cobalamin 0.538 1.31 0.559–3.046
Red cell folate 0.464 1.20 0.738–1.945
MCHC Serum cobalamin 0.351 1.48 0.653–3.315
Red cell folate 0.226 1.28 0.860–1.900
MCV Serum cobalamin 0.284 0.84 0.604–1.158
Red cell folate 0.784 1.02 0.883–1.179
PCV Serum cobalamin 0.247 1.52 0.749–3.081
Red cell folate 0.057 1.47 0.989–2.193
Platelet count Serum cobalamin 0.318 0.96 0.922–1.996
Red cell folate 0.301 0.97 0.955–1.987
Reticulocyte count Serum cobalamin 0.094 2.90 0.025–1.000
Red cell folate 0.156 8.18 0.010–1.000
Reticulocyte index Serum cobalamin 0.099 0.01 0.000–57.124
Red cell folate 0.154 0.01 0.000–98.356
WBC Serum cobalamin 0.287 0.68 0.337–1.379
Red cell folate 0.186 0.82 0.612–1.100
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chiatric patients on admission compared to those on out-patients
follow-up.21 However, in this study significantly low mean red cell
folate was found amongst anti-psychotic naïve psychiatric patients
compared with the controls, p-value 0.0001 but not with psychi-
atric patients on anti-psychotics, p-value 0.3500 despite the fact
that the two groups of respondents were recruited from out-
patient clinic. This finding is similar to that of other researchers22,23
while other researchers15,16,24 reported normal values.
No significant difference was noticed in the mean red cell folate
level of psychiatric patients on anti-psychotics and the controls in
this study. This may be due to the fact that anti-psychotic has sig-
nificant effect on normalization of red cell folate of patients with
psychiatric disorders.
None of the subjects had serum cobalamin level lower than the
normal reference range (20–680 pmol/l). That is serum cobalamin
was found to be normal in all subjects and controls. The report is
similar to that of other authors6 but differ from others.16,22,24 Sig-
nificantly high mean serum cobalamin compared with controls
found by some authors was mainly among patients with
Schizophrenia,16 although in this same group of patients low val-
ues was also reported by other authors.22,24 The finding of normal
serum cobalamin levels in all subjects in this study could be
explained based on the fact that most of them are recruited from
out-patients clinic where they are apparently stable compared
with those on admission in the wards or emergency units. Also,
the fact that most except two of the subjects are less than
12 months on medication ruled out the influence of anti-
psychotics on serum cobalamin. The differences in our findings
from that of other researchers could be also due to serum cobal-
amin assay methods. In this study, ELISA method which is said to
be more sensitive but less specific was used, while most other
researchers used Cobas E4.Of all the factors in the haemogram, reticulocyte count had
about 8 times and about 3 times the likelihood of influencing
low red cell folate and low serum cobalamin respectively, though
not statistically significant in both. None of the other factors had
influence on low red cell folate or serum cobalamin.
An obvious pattern in the results of the three groups of respon-
dents in this study was the closeness of the folate values to the
lower limit of 360 nmol/L. This suggests that the red cell folate ref-
erence interval for this environment may be different from the
Caucasian value.11,215. Conclusion
All our patients had Serum cobalamin levels within the refer-
ence interval, the same can be said of the RBC folate levels of the
greater percentage (95.5%) of psychiatric patients on psychotropic
drugs. However, folate deficiency was present in 13.6% of newly
diagnosed anti-psychotic naive psychiatric patients with few of
them having neutrophil hypersegmentation (7.6%) and macrocyto-
sis (4.5%).
RECOMMENDATIONS: Since there was a significantly low
mean red cell folate levels of antipsychotic-naïve patients com-
pared with that of controls, routine folic acid supplement should
be part of the initial treatment with antipsychotic drugs in these
patients. More studies need to be carried out on a larger number
of respondents since there is need to have reference values for
our environment in view of the low red cell folate recorded in
most of our subjects.Conflict of interest
The authors declared that there is no conflict of interest.
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